|Friday, February 21|
|CS12 Graphics in Oncology Drug Development||
Fri, Feb 21, 1:30 PM - 3:00 PM
Statistical Graphics in GSK Oncology Drug Development- Our Road to Advanced Graphic Capabilities and Insight (302756)*Michael Gabriel Durante, GlaxoSmithKline
Keywords: GSK, Oncology, GlaxoSmithKline, Graphics, Michael Durante
The primary goal of this presentation will be to highlight the role statistical graphics has played within oncology drug development at GSK over the years. Graphics often play a key role in the data review and drug approval process, from helping to identify, isolate, and explain potential safety signals to highlighting potential trends in efficacy. Graphical approaches at the patient, subgroup, study and cross-study level will be shared. The foundations of the history and development of our strong graphics culture as well as standard software advances will be discussed.
A handful of recent examples of complex, multi-level graphics which have had a real impact on drug development will also be highlighted. These will include an example of a hybrid graphic which played a major role in investigating the potential patterns in survival and progression free survival data for a recent approval will be shared. Additionally, an example which provided a high level picture of the longitudinal safety signals for a particular subgroup of patients in a recently submitted study will also be shared.